drug
ANASTROZOLE
Marketedupdated 5mo agoby Stason Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7indications
investigational
Breast Cancer
all catalysts(11)
approval · 11
Jun 28, 2010
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Jun 28, 2010
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Nov 14, 2011
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Nov 28, 2011
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Aug 13, 2015
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Aug 13, 2015
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Nov 5, 2015
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Nov 5, 2015
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Feb 21, 2025
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Oct 24, 2025
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Oct 24, 2025
approval
ANASTROZOLE — FDA approval
ANASTROZOLE
→
Trials studying ANASTROZOLE
- phase3A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- phase4Roll-over Study to Allow Continued Access to Ribociclib
- phase1A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- phase3Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
- phase3A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- phase3OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- phase3An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- phase3Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
News(2)
- AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger marketSERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.biospace · 19d ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 5mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that